吡格列酮用于2型糖尿病或高危患者心血管及肾脏结局的一级和二级预防:一项Meta分析
该Meta分析纳入26项随机对照试验共19645例2型糖尿病或高危患者,评估吡格列酮对心血管和肾脏结局的影响。吡格列酮降低主要不良心血管事件风险(RR 0.8),获益仅见于已有心血管病史者;增加心力衰竭住院风险(RR 1.3),对全因死亡无影响;降低白蛋白尿18.5%。作者认为应考虑用于心血管终点预防,尤其已有心血管病史者可能获益最大。
要点
- 吡格列酮降低主要不良心血管事件风险(RR 0.8,95%CI 0.7-0.9),获益仅见于已有心血管病史者。
- 吡格列酮增加心力衰竭住院风险(RR 1.3,95%CI 1.1-1.6),对全因死亡无影响(RR 1.0)。
- 吡格列酮降低白蛋白尿18.5%(WMD 18.5%,95%CI 21.1-16.0),不同肾功能类别获益相似。
核心结论
- 作者认为,对于2型糖尿病或高危患者,应考虑使用吡格列酮预防心血管终点,尤其已有心血管病史者可能获益最大。
- 无论基线肾功能程度如何,均可见肾脏疾病进展的显著降低。
研究设计与样本
- 通过PubMed、Embase和Cochrane Library检索比较吡格列酮与任何对照的随机对照试验。
- 共纳入26项研究,19645例参与者。
- 采用加权均数差(WMD)和风险比(RR)及95%置信区间(CI)进行合并。
主要发现
- 吡格列酮降低主要不良心血管事件风险(RR 0.8,95%CI 0.7-0.9),获益仅见于已有心血管病史者(RR 0.8,95%CI 0.7-0.9),无心血管病史者未见获益(RR 1.0,95%CI 0.7-1.3)。
- 吡格列酮降低非致死性心肌梗死风险(RR 0.8,95%CI 0.6-1.0)和非致死性卒中风险(RR 0.8,95%CI 0.7-0.9),且仅限于已有心血管病史者。
- 无论是否存在已确立的心血管疾病,吡格列酮对心血管死亡均无治疗效应(RR 1.0,95%CI 0.7-1.2)。
- 吡格列酮增加心力衰竭住院风险(RR 1.3,95%CI 1.1-1.6),对全因死亡无治疗效应(RR 1.0,95%CI 0.8-1.1)。
- 吡格列酮降低白蛋白尿18.5%(WMD 18.5%,95%CI 21.1-16.0),不同肾功能类别患者获益相似。
临床怎么用
- 作者认为,对于2型糖尿病或高危患者,应考虑使用吡格列酮预防心血管终点,尤其已有心血管病史者可能获益最大。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The goal of the meta-analysis was to evaluate the effect of pioglitazone on the primary and secondary prevention of cardiovascular diseases (CVDs) and renal adverse events in patients with or at high risk of type 2 diabetes mellitus (T2DM). DESIGN: Randomized controlled trials (RCTs) comparing pioglitazone with any control were identified through PubMed, Embase, and the Cochrane Library. Cardiovascular outcomes included major adverse cardiovascular events (MACEs, defined as the composite of nonfatal myocardial infarction, nonfatal stroke, and cardiovascular death), hospitalization for heart failure, and all-cause mortality. Renal outcomes included change in urinary albumin to creatinine ratio and 24-hour urinary protein excretion. Weighted mean difference (WMD) and risk ratio (RR) with 95% confidence intervals (CIs) were pooled. RESULTS: A total of 26 studies with 19 645 participants were enrolled. Pioglitazone reduced the risk of MACE (RR, 0.8 [95% CI, 0.7-0.9]), with benefit only seen in patients with a history of established CVDs (0.8 [0.7-0.9]) and not in those without (1.0 [0.7-1.3]). Regarding the individual components, pioglitazone reduced the risk of nonfatal myocardial infarction (0.8 [0.6-1.0]) and nonfatal stroke (0.8 [0.7-0.9]), which was confined to patients with a history of established CVDs, whereas no treatment effect was found on cardiovascular death (1.0 [0.7-1.2]) regardless of the presence of established CVDs. Pioglitazone increased the risk of hospitalization for heart failure (1.3 [1.1-1.6]) and had no treatment effect on all-cause mortality (1.0 [0.8-1.1]). Pioglitazone reduced albuminuria by 18.5% (WMD 18.5% [95% CI, 21.1-16.0]), with a similar benefit in patients with different renal function categories. CONCLUSIONS: Pioglitazone should be considered in patients with or at high risk of T2DM for the prevention of cardiovascular endpoints, especially in those with a history of established CVD who might benefit the most. Robust reductions in progression of renal disease are seen regardless of baseline renal function degree.
引用
- Zhou Y, Huang Y, Ji X, et al. Pioglitazone for the Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Patients with or at High Risk of Type 2 Diabetes Mellitus: A Meta-Analysis. J Clin Endocrinol Metab. 2020. PMID: 31822895. doi:10.1210/clinem/dgz252
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。